Inotiv, Inc. (NOTV) Dividend History

Inotiv, Inc. (NOTV) is a contract research organization (CRO) that provides research and development services primarily to biopharmaceutical and biotechnology companies. The company specializes in preclinical research, including pharmacology, toxicology, and ADME (absorption, distribution, metabolism, and excretion) testing, supporting drug discovery and development processes. Inotiv operates laboratories across the United States and offers tailored solutions to accelerate the development of new therapies.

2701 Kent Ave, West Lafayette, IN, 47906-1382
Phone: (317) 463-4527
Website:

Dividend History

Inotiv, Inc. currently does not pay dividends

Company News

  • Inotiv, Inc. Provides Business Updates

    WEST LAFAYETTE, Ind., June 10, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today provided the following business updates:

    GlobeNewswire Inc.
  • Inotiv Reaches Agreement to Resolve Previously-Announced Investigation into Shuttered Cumberland Facility

    Company reaffirms commitment to maintaining appropriate standards of animal welfare Company reaffirms commitment to maintaining appropriate standards of animal welfare

    GlobeNewswire Inc.
  • Inotiv, Inc. to Participate in Upcoming Craig Hallum and Jefferies Investor Conferences

    WEST LAFAYETTE, Ind., May 23, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in the upcoming 21st Annual Craig Hallum Institutional Investor Conference and Jefferies Global Healthcare Conference.

    GlobeNewswire Inc.
  • Inotiv, Inc. Reschedules its Fiscal 2024 Second Quarter Results

    WEST LAFAYETTE, Ind., May 09, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the release of the Company’s financial results for the three and six months ended March 31, 2024 and the conference call to discuss the results that were originally scheduled for Friday, May 10, 2024 are being rescheduled to provide the Company additional time to complete the accounting analyses related to certain matters. Specifically, as previously disclosed, the Company has been cooperating with the U.S. Department of Justice (the “DOJ”) and other authorities related to an investigation by those authorities into various matters relating to the previously disclosed execution of a search and seizure warrant at the Company’s Cumberland, Virginia facility. Due to the current status of negotiations between the Company and the DOJ regarding a potential resolution, as well as related actions that would need to occur in order for any such resolution to be finalized, including, without limitation, negotiations between the Company and DOJ regarding mutually satisfactory resolution documents, final approvals by DOJ and the Company, and depending on the terms of any final resolution with the DOJ, negotiations with certain of the Company’s stakeholders regarding the feasibility of such proposed resolution, the Company requires additional time to complete the analysis of this subsequent event and the related accounting matters. The Company is working diligently to complete these analyses and finalize its financial statements as soon as possible.

    GlobeNewswire Inc.
  • Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Misses Revenue Estimates

    Crinetics Pharmaceuticals (CRNX) delivered earnings and revenue surprises of -10.71% and 21.47%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Investment Research
    Featured Companies: CRNX
Dividend data last updated 06/06/2025 22:41:00 UTC